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SUMMARY 
Duchenne Muscular Dystrophy (DMD) is a hereditary X-linked fatal disease that affects 1 in 
3500 male births. It is the most common kind of muscular dystrophy in children and leads to 
death in the late teens or early 20s for many patients. The mdx mouse is a model of DMD that 
can be used to investigate experimental therapies. Overexpression of a glycosyltransferase, 
CT GalNAc, in mdx mice has been demonstrated to prevent the development of muscular 
dystrophy. Overexpression of another glycosyltransferase, LARGE, is currently being 
investigated as a treatment for another group of muscular dystrophies, the 
dystroglycanopathies.  
In this study, we overexpressed LARGE in mdx mice in order to investigate its effect on the 
development of muscular dystrophy. We found that the transgene was expressed in our 
LV5/mdx mice, as seen with both immunohistochemistry and western blots, but that 
overexpressing the enzyme unfortunately appeared to have a negative effect on the dystrophy. 
An increase in pathology was seen histologically at both 3 and 8 weeks of age in the LV5/mdx 
mice when compared to the mdx mice. Physiological measurements on 22 week old mice 
showed a significantly diminished tolerance to eccentric exercise in the LV5/mdx compared to 
their mdx littermates. These observations lead us to the conclusion that increased expression 
of LARGE is not a therapeutic option for DMD patients, but is in fact contraindicated. 
SAMMANFATTNING 
Duchenne Muskulär Dystrofi (DMD) är en ärftlig X-linkad dödlig sjukdom som drabbar en 
av 3500 födda pojkar. Det är den vanligaste förekommande typen av muskulär dystrofi hos 
barn och leder till döden från sena tonår till tidig 20-års ålder för många av de drabbade. mdx-
musen är en modell för DMD som kan användas för att utvärdera experimentella 
behandlingar. Överuttrycket av ett glykosyltransferas, CT GalNAc, hos mdx-musen har visat 
sig förhindra utvecklingen av muskulär dystrofi. Överuttrycket av ett annat 
glykosyltransferas, LARGE, undersöks just nu som en möjlig behandling för en annan grupp 
muskulära dystrofier, dystroglykanopatierna. 
I den här studien har vi överuttryckt LARGE hos mdx-möss för att kunna undersöka dess 
effekt på utvecklingen av den muskulära dystrofin. Vi fann att transgenen uttrycktes hos våra 
LV5/mdx-möss med hjälp av både immunohistokemi och western blot, men att överuttrycket 
av enzymet tyvärr hade en negativ effekt på utvecklingen av dystrofin. En ökad nivå av 
patologi kunde ses på histologi gjord hos både 3 och 8 veckor gamla LV5/mdx-möss vid 
jämförelse med mdx-möss. Fysiologiska mätningar gjorda på 22 veckor gamla möss visade en 
signifikant minskad tolerans för excentrisk belastning hos LV5/mdx jämfört med deras mdx 
syskon från samma kull. Dessa iakttagelser fick oss att dra slutsatsen att ett ökat uttryck av 
LARGE hos DMD-patienter inte är ett alternativ för behandling, utan måste anses 
kontraindicerat. 
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Abbreviations 
α-DG – alpha-dystroglycan 
β-DG – beta-dystroglycan 
BMD – Becker Muscular Dystrophy 
CMD – Congenital Muscular Dystrophy 
CT GalNAc – Cytotoxic T cell GalNAc transferase 
DAPs – Dystrophin associated proteins 
DMD – Duchenne Muscular Dystrophy 
DPM3 – DOL-P-Man synthase subunit 3 
ECM – Extracellular matrix 
FCMD – Fukuyama congenital muscular dystrophy 
H&E – Haematoxylin and eosin staining 
LGMD – Limb-Girdle Muscular Dystrophy 
LV5 – mouse overexpressing LARGE 
LV5/mdx – mdx mouse overexpressing LARGE 
MD – muscular dystrophy 
MEB – Muscle-eye-brain disease 
POMGnT1 – Protein-O-mannose 1,2-Nacetylglucosaminyltransferase 1 
POMT1 – Protein-O-mannosyl transferase 1 
POMT2 – Protein-O-mannosyl transferase 2 
TA – Tibialis Anterior 
WT – wild type mouse 
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INTRODUCTION AND LITTERATURE REVIEW 
Muscular dystrophy (MD) is a group of hereditary diseases which are characterised by 
muscular weakness as a result of skeletal muscle wasting. There are many types of MD listed 
according to varying degrees of symptoms, location and age for onset of disease, such as 
Becker Muscular dystrophy (BMD), Duchenne Muscular dystrophy (DMD), Emery-Dreifuss 
muscular dystrophy, Congenital muscular dystrophy (CMD) and Limb-girdle muscular 
dystrophy (LGMD). Symptoms may start manifesting at birth or as late as in the 60s, and may 
include mental retardation (CMD) and cardiomyopathy (DMD, Emery-Dreifuss, LGMD) 
(Emery, 2002). The major cause of MDs is mutations in structural proteins such as dystrophin 
(DMD, BMD), sarcoglycans (forms of LGMD) or laminin (forms of CMD). 
A new cause of MD has emerged during the last decade, with mutations in proteins that are 
putative or demonstrated glycosyltransferases causing a range of different clinical types of 
muscular dystrophy (Michele et al., 2002). The mutations result in a defective glycosylation 
of alpha dystroglycan (α-DG), leaving it hypoglycosylated. α-DG is a component of the 
dystrophin-glycoprotein complex present at the sarcolemma of skeletal muscle which 
undergoes glycosylation to regulate its ability to interact with extracellular matrix (ECM) 
proteins, changing between a hypoglycosylated and a hyperglycosylated state (Ervasti & 
Campbell, 1991). Mutations in seven genes coding for demonstrated or putative 
glycosyltransferases causing hypoglycosylation of α-DG have been identified so far: Protein-
O-mannosyl transferase1 (POMT1; OMIM 607423; Beltran-Valero de et al., 2002), Protein-
O-mannosyl transferase 2 (POMT2; OMIM 607439; van Reeuwijk et al., 2005), Protein-O-
mannose 1,2- Nacetylglucosaminyltransferase1 (POMGnT1; OMIM 606822; Yoshida et al., 
2001), Fukutin (OMIM 607440; Kobayashi et al., 1998), Fukutin-related protein (FKRP; 
OMIM 606596; Brockington et al., 2001), LARGE (OMIM 603590; Longman et al., 2003) 
and DOL-P-Man synthase subunit 3 (DPM3; OMIM 605951; Lefeber et al., 2009). Mutations 
in some of these are known to cause forms of CMD and LGMD, and they form part of the 
group of diseases caused by defective glycosylation of α-DG, now called 
dystroglycanopathies. 
Duchenne Muscular Dystrophy 
Duchenne Muscular Dystrophy (DMD) is the most common MD in children and was first 
described in 1851 (Meryon E, 1851). It is a fatal, X-linked recessive disease that affects 
approximately 1 in 3500 male births (Hoffman, 1987). The patients show delayed motor 
development and fail to meet motor milestones, such as starting walking and running, and 
patients often get diagnosed with the condition at a young age. The disease then progresses 
with increasing weakness, loss of ability to walk, scoliosis and in the late stages of the 
disease, cardiac and respiratory failure leading to death. Many patients die in their late teens 
or early 20s.  
The disease is caused by mutations in the dystrophin gene, the largest gene on the X-
chromosome. Different mutations have been associated with the disease, but they most 
commonly lead to a disruption of the open reading frame, which results in failure to translate 
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the mRNA into a functional protein. Patients suffering from this disease therefore have no 
dystrophin in their muscles, a structural protein normally located at the sarcolemma of the 
muscle fibres. This makes the muscle membrane fragile and prone to necrosis, leading to 
extensive damage. The tissue is progressively replaced by fibrosis and fatty connective tissue 
with time as the pool of satellite cells, the stem cells of skeletal muscles, is depleted (Cossu & 
Mavilio, 2000). BMD, which ranges from almost asymptomatic to close to DMD in clinical 
presentation, is associated with in frame mutations in the dystrophin gene, leading to a 
truncated protein. There is today no cure for either of these diseases, but some treatments, 
such as corticosteroids, can slow down the progression and give a better quality of life.  
Approximately two-thirds of mothers of DMD patients are thought to be carriers of the 
defective gene, while the remaining cases represent new mutations occurring spontaneously in 
the dystrophin gene (Dubowitz, 1982). Of these carriers, approximately 8% show some kind 
of clinical symptoms. The female patients with manifesting disease show a symptom severity 
that inversely correlates with the proportion of the normal X-chromosome being expressed 
(via X inactivation), with a lower proportion giving more severe disease. 
mdx – a mouse model for DMD 
As many other animal models, the mouse model for DMD was discovered by chance when 
screening was performed on mice for another experiment (Bulfield et al., 1984). It was later 
confirmed that this mouse indeed suffered from the same genetic disorder as the human 
patients, despite not showing the same clinical phenotype (Hoffman, 1987). It has a 
widespread use today in research for both DMD and BMD.  
The mdx mice suffer from a mutation that occurred spontaneously in the dystrophin gene, 
creating a premature STOP codon located in exon 23 of the gene transcript. The translation of 
the dystrophin mRNA into protein is therefore made impossible, making the mouse 
dystrophin deficient. The absence of dystrophin makes the sarcolemma more fragile, resulting 
in increased necrosis of skeletal muscle fibres just as in the human patient.  
There is an acute onset of pathology observed in the mdx mouse at around 3 weeks of age 
with massive muscle fibre necrosis and an increase in blood creatine kinase. This stimulates 
muscle regeneration in the areas of destruction, giving rise to patches of small, dystrophic 
myofibres with central nuclei. The nuclei will stay central for many months before a very 
small proportion of them become peripheral, making it easy to identify regenerated fibres at 
the histological level. The level of necrosis is stabilized by 8 weeks of age, staying on a 
relatively low level of active damage until the mouse reaches one year, when it is reduced 
even more. Differences in the pathology are seen depending on the muscle observed, e.g. with 
the diaphragm displaying more severe pathology than the muscles of the hind limb (Grounds 
et al., 2008). 
The pathology observed in the mouse model is much less severe than in humans suffering 
from the disease. This may be due to the difference in weight and in load on the muscles, but 
also the difference in the locomotor apparatus, comparing a biped to a quadruped (Grounds et 
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al., 2008). The mild phenotype observed in the mdx mouse may also mean that the pool of 
satellite cells lasts its whole lifetime, resulting in less extensive fibrosis compared to humans 
(Cossu & Mavilio, 2000). 
LARGE as a possible treatment for MD 
Mutations in the putative glycosyltransferase LARGE is one of the seven causes of 
dystroglycanopathy reported so far. It is a protein ubiquitously expressed in the body that is 
mainly confined in the Golgi apparatus within the cell (Brockington et al., 2005). Viral gene 
transfer into cell cultures derived from patients suffering from dystroglycanopathies suggests 
that this particular enzyme can functionally compensate for other glycosylation defects 
(Barresi et al., 2004) and later, this was also demonstrated in vivo in a mouse model 
(Kangawa et al., 2009). Seeing as only very few cases of patients with mutations in LARGE 
has been reported worldwide (Mutoni et al., 2008), this discovery displays a very big 
therapeutic potential for the dystroglycanopathies. In addition, Nguyen et al (2002) and 
Martin et al (2009) discovered that the overexpression of CT GalNAc, another 
glycosyltransferase localized in the neuromuscular synapses in adult skeletal muscles, 
prevents MD development in mdx mice when looking at both the histology and physiology.  
Following these publications, a mouse overexpressing LARGE was generated by Brockington 
et al (2010), showing no histological pathology in any muscles. This now opens up the 
possibility of assessing the potential for upregulation of LARGE expression as a therapy for a 
range of muscular dystrophies by crossing this transgenic with the different mouse models of 
muscular dystrophy. 
This investigation has been aimed at assessing if the overexpression of LARGE in mdx mice 
can prevent the development of MD, by looking at different time points and using different 
techniques for assessing histopathology and physiology. 
MATERIALS AND METHODS 
Genotyping 
Mice overexpressing LARGE were generated as described in Brockington et al (2010). These 
were crossed with mdx mice, and the offspring were genotyped by using PCR to identify the 
transgenic individuals. Ear biopsies taken after weaning were put in 100 µl ear buffer 
(originating from a 10x stock solution consisting of 500 mM KCl; 100 mM Tris-HCl pH 8,3; 
0,1 mg/ml Gelatin; 0,45% v/v Tween 20; 0,45% v/v Nonidet P40; 5 mg/ml Proteinase K) and 
left overnight in a 50°C water bath to digest the proteins and liberate the DNA. The following 
day, they were heated in a block at 100°C for 10 minutes to degrade the proteinase K used to 
digest the biopsy. 
A master mix was made up based on the basic recipe of 17 µl of double distilled water, 2,5 µl 
of buffer, 2,5 µl enhancer solution, 0,5 µl of MgCl (50 mM), 0,75 µl of dNTP (2,5 mM/ 
nucleotide), 0,5 µl of forward (T7; TAATACGACTCACTATAGG) and reverse (LGS1; 
CTGCCCAATGCTAAGATG) primers (10 pM/µl) and 0,25 µl Taq polymerase. This made 
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up 24,5 µl of master mix that was mixed with 0,5 µl of sample that was then run in the PCR 
with the running conditions of 5 minutes at 94°C for initial denaturation, then 35 cycles of 15 
seconds at 94°C, 30 seconds at 55°C and 30 seconds at 68°C, followed by a 10 minutes final 
extension at 68°C. 
6 µl of loading buffer (Ficoll and bromophenol blue) was added to each sample before they 
were run in a 1% agarose gel (1 g agarose powder mixed with 100 ml TBE Trisboric acid 
EDTA) where SYBR safe (5 µl/100 ml gel) had been added. The gel was run at 70 V for 40 
min, and a 1 kb ladder was used. The results were visualized in a UV-box. 
Muscle Processing 
The samples collected from the mice for histology and western blots were quadriceps, 
diaphragms, soleus, Extensor Digitorium Longus (EDL) and Anterior Tibialis (AT). The mice 
were killed by cervical dislocation and the muscles dissected and mounted on pieces of cork 
with OCT and then snap frozen in isopentane that was cooled in liquid nitrogen. The samples 
were wrapped in foil and kept in a -80°C freezer. When using them for cryosectioning, the 
samples were transported on dry ice to the cryostat and left for 30 minutes to equiliberate to -
20°C. Sections were cut at 10 µm and placed on Superfrost slides. Approximately 8-12 
different levels within the muscle were collected onto the same slide and ten serial slides were 
generated. The number of sections discarded between each level in the muscle varied 
depending on tissue and age (8 week quadriceps: 40 discards, 8 week diaphragms: 25 
discards, 3 week quadriceps: 10 discards, 3 weeks diaphragm: 10 discards, 20 weeks 
diaphragm: 30 discards). The slides were left out to dry for 10 minutes before they were 
stored in a -80°C freezer. 
Staining 
Harris’s haematoxylin (ratio 1:1 with water) and 1% eosin was used for the H&E staining. 
The slides were left to air-dry for 20 minutes after removal from the -80°C freezer and then 
left for three minutes in the haematoxylin. They were then placed in running water for four 
minutes, followed by 40 seconds in eosin, after which the slides were briefly washed in water. 
The slides were then progressively dehydrated in alcohol (70%, 80%, 90% and 100%) and 
then cleared for 20 minutes, followed by another 60 minutes in xylene. DPX was used to 
mount the cover slip, and the finished slides were left to dry in the fume hood until the next 
day. Colour images were taken with the Bright Field upright DM4000B using the Leica 
Application Suite software. 
Immunohistochemistry was done on the 8 week and 3 week quadriceps using the IIH6 
antibodys. This binds to glycosylated epitopes, which in this case is primarily the 
hyperglycosylated α-DG. As before, the slides were allowed to air-dry for 20 minutes and 
then left to incubate overnight in 1:200 IIH6 at 4 °C. The following day, they were washed (3 
times for 3-5 minutes) in PBS and then left to incubate in 1:200 biotinylated polyclonal rabbit 
anti-mouse Ig M for 30 minutes. The slides were washed again and then incubated in 1:1000 
Streptavidin and 1:2000 Hoechst for 20 minutes before being washed and then mounted with 
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hydramount. They were visualized in the Fluorescent upright DM4000B microscope and 
pictures were taken using the Zeiss AxioVision software. 
Alizarin red S staining for calcium was done to confirm the presence of calcium deposits in 
the muscles of the 8 week old mice. Sections were taken from the -80°C freezer and left to 
dry for a few minutes before they were fixed in cold acetone for 10 minutes. They were then 
left to dry again before they were rinsed in distilled water. The slides were immersed in 
Alizarin red solution (Alizarin red S: 2g; Distilled water: 100 ml; pH: 4,2) for 1 minute. The 
slides were then blotted dry, before being rinsed in acetone for 30 seconds and then rinsed in 
acetone/xylene (1:1) for 15 seconds, and finally cleared in xylene for 20 minutes followed by 
another 60 minutes before they were mounted with DPX. Imaging was performed as with the 
H&E stains. 
Tiling 
In order to perform various image analyses, tiling was done with the H&E slides. This creates 
a high contrast, black and white image of the slides using a merged image of several small 
pictures. The Leica SP5 confocal microscope with the Leica Application Suite Advanced 
Fluorescence software was used to do this. These images were then used to perform counts on 
total number of fibres and number of non-centrally nucleated cells with the help of Photo 
Shop and Image J. The definition set for a non-centrally nucleated cell was any muscle fibre 
that had nuclei that were in contact with the membrane, or were not further away from the 
membrane than the diameter of a nucleus. Any fibre that had no visible nucleus in the section, 
but had a clearly darker colour than the surrounding fibres, was regarded as a regenerating 
fibre and therefore not counted as a non-centrally nucleated fibre. The area counted was 
limited to the rectus femoris as this muscle was well limited and undamaged in most of the 
sections. Three counts of total number of fibres were done per group (n=3) and averages were 
based on these. The counts of non-centrally nucleated fibres were done blinded to sample 
identity. 
Western blot 
Protein extraction was performed in a sample buffer consisting of Tris HCl 75 mM, pH 6,8; 
SDS 1% and a protease inhibitors (Complete, Mini; Protease Inhibitor Cocktail Tablets, 
Roche according to manufacturer’s instructions).  The muscles were first weighed, and then 
crushed with a pestle and mortar that had been cooled down with liquid nitrogen. The 
powdered muscle was collected in eppendorfs and sample buffer added (2µl/ mg tissue). The 
samples were then heated (3 minutes in 100 °C) and then centrifuged (10 minutes at 14 000 g 
at 4 °C).The supernatant was transferred into new eppendorfs. The samples were then stored 
on dry ice until a protein quantification assay was performed on them. Quantification of the 
total protein in each sample was performed using the DC Protein Assay (BIORAD) on 
samples than had been diluted 1:20 with filtered water. Standards were made up according to 
instructions in the Comassie Plus Protein Assay Reagent kit. After quantification the samples 
were aliquoted and stored at – 80°C. 
7 
 
Polyacrylamide gel electrophesis was perfomed in a XCell SureLock™ Mini-Cell (Invitrogen) 
using precast NuPage Novex Bis Tris 4-12% gradient gels according to manufacturer’s 
instructions. 20 µl total volume was loaded per well, consisting of 20 µg of total protein, 1 µl 
of NuPage Sample Reducing Agent (10x), 5 µl of NuPage 4X LDS Sample Buffer and RO 
water. Electrophoresis was performed in NuPage 1 X MOPS SDS Running Buffer with 0.5 ml 
of NuPage Antioxidant. The gel was run at 200 V for 90 minutes. 
Transfer of the proteins to a nitrocellulose membrane (HybondC – GE Healthcare) was 
performed in an XCell II™ Blot Module (Invitrogen) according to manufacturer’s instruction, 
in 1 X NuPage Transfer Buffer at 30V for 2h 30 minutes. After transfer the membrane was 
transferred into blocking solution, 3% BSA (Jackson ImmunoResearch) in IIH6 blocking 
buffer (100 mM NaCl; 20 mM Tris pH 7.4) overnight at 4C. 
Immunostaining was performed with monoclonal antibody IIH6 (1:2500) or polyclonal 
Rabbit anti- β-tubulin antibody diluted in IIH6 blocking buffer with 3% BSA for 1 h on the 
roller mixer at room temperature. The membrane was washed thoroughly (3 X 10 minutes in 
IIH6 blotting buffer) before incubation with the secondary antibodies, either polyclonal rabbit 
anti-mouse IgM biotinylated antibody (1:2000) for IIH6 or anti-rabbit Ig G HRP conjugate for 
β-tubulin (1:5000). Secondary antibodies were diluted in IIH6 blotting buffer and incubated 
for 1 h at room temperature. The membrane was washed (3 x 10 minutes in IIH6 blotting 
buffer). For IIH6 staining a further round of signal amplification was performed with 
Streptavidin-HRP conjugate (1:10 000) diluted in IIH6 Blotting Buffer incubated for 1hour at 
room temperature. The membrane was washed again in IIH6 blotting buffer. Antibodies were 
visualised using an ECL plus chemiluminescence detection system (GE Healthcare, according 
to manufacturer’s instructions). The membranes were exposed to x-ray films in a dark room 
to obtain the clearest result. 
Physiology 
Physiology was performed on both groups of mice at 22 weeks of age, using methods 
described in Brockington et al (2010).  The distal tendon of the TA of anaesthetised mice was 
dissected from surrounding tissue and attached to a servomotor transducer in order to record 
several physiological measurements, such as the peak twitch force, maximum isometric 
tetanic force and the susceptibility of the TA muscle to eccentric contraction-induced injury. 
This was done while carefully monitoring the mouse and using previously tested protocols for 
the different measurements. 
RESULTS 
Generation of LV5/mdx mice 
Male mice overexpressing LARGE (described in Brockington et al., 2010) were crossed with 
female mdx mice, generating offspring where in theory 50% of the pups should be carrying 
the LARGE gene and all the male mice were mdx as the mdx allele is on the X chromosome. 
The pups were genotyped using PCR, and then separated into one experimental group 
(LV5/mdx) and a control group (mdx) with littermates present in both groups (Figure 1). In 
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subsequent generations LV5/mdx male mice were crossed with mdx females so that both 
sexes could be used. 
                  
Figure 1. Genotyping offspring of LV5 and mdx mice. 15 ear samples followed by water (negative 
control), two known LV5 positive controls and ear buffer (EB, negative control). Positive samples in 
wells 3, 4, 5, 6, 9, 11, 12, 13 and 15. 
 
Time point 8 weeks 
The first time point we chose for comparison was 8 weeks. At that point, the level of necrosis 
in the mdx model should have stabilized to a relatively low level and fibres in all stages could 
be seen in the muscle. We started off looking at quadriceps from the two groups. 
When examining the blinded H&E slides from 8 week quadriceps (n= 6 per genotype, all 
males), deposits of some kind were found in almost all of the samples. There was a varying 
degree of destruction and inflammation seen in the tissue, but some differences were observed 
that made it possible to separate the mice into two groups (figure 2). Differences in the 
number of fibres with centralized nuclei, and in the morphology of the fibres were observed. 
One group, which was found to be the LV5/mdx, appeared to have almost 100% fibres with 
centralized nuclei, whereas the other group, mdx, had a more visible proportion of fibres with 
non-centrally nucleated fibres. This observation was confirmed when counting of the fibres 
was done on tiled images (figure 3), showing a clear significant difference (p<0,0001) 
between the two groups when performing an unpaired t-test with the percentage of non-
centrally nucleated fibres (figure 4). The LV5/mdx also appeared to be more heterogeneous in 
fibre size than the mdx. They displayed groupings of very small regenerating fibres, and 
groups of big fibres. 
We proceeded to look at the diaphragms of the same individuals (n=6 per genotype, all 
males). As expected, the pathology in this tissue was more severe than that observed in the 
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quadriceps as it is a muscle that is in constant use. The deposits found in the quadriceps were 
also found in the diaphragms when looking at the slides after H&E staining, but they were 
present in larger quantities. As they were suspected to be calcium deposits, alizarin red 
staining was performed. This stains the calcium present in the sample intensely red and makes 
it easily distinguishable from the rest of the tissue. The suspicion about calcium was 
confirmed as the deposits stained very intensely (figure 5). There was also a clear difference 
observed between the two groups, with the LV5/mdx showing a bigger quantity of deposits 
located throughout the diaphragm. The mdx had a smaller quantity of deposits that was 
frequently located in one area. 
The findings made at this time point indicated a more severe pathology in the LV5/mdx mice 
compared to the mdx. The decision to look at an earlier time point was made, in order to 
investigate whether the pathology in the LV5/mdx started earlier than in the mdx, or if it had 
the same starting point but with a more intense pathological development. 
 
Figure 2. Rectus femoris muscle in 8 week old mdx and LV5/mdx mice. H&E staining of transverse 
cryosections of quadriceps from mdx (A and B) and LV5/mdx (C and D) mice. More centralized 
myonuclei can be seen in the LV5/mdx mouse compared to the mdx mouse. Scale bar 500 µm in A and 
C, and 100 µm in B and D. 
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Figure 3. Tiling of images to show the 
complete rectus femoris on a LV5/mdx 
mouse. 
 
 
Figure 4. Percentage of non-centralised 
myonuclei in 8 week old mdx and 
LV5/mdx mice. Results are expressed as 
mean ± standard deviation of percentage 
non-centralised myonuclei in relation to total 
number of fibres in the rectus femoris (n=6 
per group). The number of non-centralised 
myonuclei is significantly higher in the mdx 
compared to the LV5/mdx. *** p<0,0001 for 
comparison between mdx and LV5/mdx with 
unpaired t-test. 
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Figure 5. Diaphragm in 8 week old mdx and LV5/mdx mice. Transverse frozen sections of 
diaphragm in mdx (A and B) and LV5/mdx mice (C and D). H&E staining (A and C) and alizarin red 
staining (B and D). The presence of more calcium deposits in a larger area is seen in the LV5/mdx 
compared to the mdx. Scale bar-500 µm. 
 
Time point 3 weeks 
The pathology in the mdx mice is said to start at 3 weeks of age (Grounds, 2008). We 
therefore decided to take this as the next time point for investigation. The mice chosen were 
20 days old and originated from three litters.  
When looking at the samples blinded, the quadriceps could be grouped into two groups (n=5; 
LV5/mdx: 1 female, 4 males; mdx: 1 male, 4 females) based on the degree of destruction and 
inflammation. The LV5/mdx showed a much higher degree of destruction and inflammation 
than the mdx (figure 6). The destruction was seen in various places in the quadriceps muscle, 
sometimes being only apparent in the rectus femoris and not at all in the vastus muscles 
(musculus vastus medialis, lateralis et intermedius), other times completely the opposite. No 
apparent pattern of destruction could be determined. 
The diaphragms of the same individuals (n=5) were examined, but no clear difference could 
be observed. 
12 
 
 
Figure 6. Quadriceps mucle in 3 week old mdx and LV5/mdx mice. Transverse frozen sections of 
quadriceps in mdx (A and B) and LV5/mdx (C and D) mice. H&E staining. The individuals with the 
least amount of damage within their group (A and C) and the individuals with the greatest amount of 
damage (B and D). The overall level of damage observed is much greater in the LV5/mdx mice 
compared to the mdx mice. Scale bar- 500 µm. 
 
IIH6 staining 
The IIH6 staining was done on sections of quadriceps from the 3 and 8 week mice in order to 
confirm the overexpression of LARGE in the muscle. Confirmation was obtained in all the 8 
week samples, as a clear difference could be seen between the two groups when viewed 
blinded (figure 7). The IIH6 was seen bound in much greater quantities in the sections 
originating from LV5/mdx mice, displaying a clear outline of the individual muscle fibres. A 
similar difference was observed when looking at the 3 week quadriceps. 
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Figure 7. Immunohistochemistry of mdx and LV5/mdx mice quadriceps. Transverse frozen 
sections of quadriceps from mdx (A and C) and LV5/mdx (B and D) mice aged 3 weeks (A and B) and 
8 weeks (C and D) stained with IIH6 antibodies. The LV5/mdx individuals show a much more intense 
staining compared to the mdx, confirming the expression of the LARGE transgene. Scale bar-100 µm. 
Time point 20 weeks 
With the difference seen between the two groups at an early stage, the question whether a 
difference could be observed at a later stage as well arose.  A small number of mice aged 20 
weeks were selected to have a preliminary look (LV5/mdx, n=2; mdx, n=1; all males). The 
difference most likely to be seen at this stage was in the development of fibrosis, and 
therefore the diaphragm was examined. When the H&E slides were viewed blinded, there was 
a clear development of fibrosis observed. Deposits were present in large quantities, and many 
hypertrophied fibres were seen (figure 8). No clear difference could be established between 
the two groups. 
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Figure 8. Diaphragm of a 20 week old mdx and LV5/mdx mouse. Transverse frozen sections of 
diaphragm from mdx (A) and LV5/mdx (B) mice at 20 weeks. No difference between the two groups 
could be established. Scale bar-200 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. In vivo response to lengthening contraction. Percentage of force drop during eccentric 
exercise protocol with a 15% stretch of the TA in 22 week old mice (n=3 per group). Results are 
expressed as mean ± standard error of mean. The LV5/mdx mice showed significantly greater force 
drop compared to the mdx littermates with increasing number of contractions (p=0,0086 between the 
two curves). 
 
Physiology 
As there was no clear difference seen between the two groups histologically in the diaphragm 
in the older mice, we investigated if there was a physiological difference. Physiological 
measurements was done by Rebecca Terry on 22 week old mice (n=3 for both genotypes, all 
males) as previously described (Brockington et al., 2010). The eccentric exercise protocol 
showed a clear significant difference (p=0,0086 with repeated measures ANOVA) between 
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the two groups, with one displaying an earlier and more rapid decrease in force than the other. 
The LV5/mdx group showed a much decreased tolerance to the contractions compared to the 
mdx as the decrease in force observed indicates muscle damage (Figure 9). 
Western blot 
We used paired samples for both groups at 3 and 8 weeks of age (n=2 per group, all males) as 
well as a WT and a LV5 (n=1, male) (figure 10). The blot showed the normal glycosylation in 
the WT and the expected hyperglycosylation in the LV5. The 3 week mdx showed almost no 
glycosylation, whereas the 8 week mdx showed a limited level. The LV5/mdx displayed a 
clear hyperglycosylation at both time points, which confirms the presence and expression of 
the LARGE transgene in these animals. Similar results were obtained for another 3 samples 
from 8 week mice (n=3 per group, all males) in western blots performed by Dr Mark 
Ackroyd. 
 
Figure 10. Western blot of mouse muscle. Western blot analysis of protein lysates with IIH6 
antibodies against α-DG. Quadriceps muscle from LV5 (lane 1), WT (2), 3 week mdx (3 and 4), 8 
week mdx (5 and 6), 3 week LV5/mdx (7 and 8), 8 week LV5/mdx (9 and 10). Hyperglycosylation can 
be seen in lane 1, 7, 8, 9 and 10. Upper arrow shows hyperglycosylation while the lower arrow shows 
normal glycosylation. 
 
DISCUSSION 
Overexpression of LARGE represents one of the many strategies being pursued to find a 
treatment for DMD and other MDs. It has been demonstrated that overexpression of LARGE 
increases the glycosylation of α-DG (Brockington et al., 2005), which is the process that is 
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defective in dystroglycanopathies. If proven successful, the LARGE initiative has the 
potential for treating a number of MDs, especially since even partial restoration of α-DG 
glycosylation can ameliorate the progression of the diseases noticeably (Kanagawa et al., 
2008).  
Unfortunately, this study reveals that LARGE is not alternative therapeutic option for DMD 
patients. At 3 weeks, the LV5/mdx mice show a more severe pathology with an earlier onset 
compared to the mdx mice. This is once again seen at 8 weeks when the LV5/mdx mice had 
more advanced pathology as indicated by the significantly reduced count of non-centrally 
nucleated fibre compared to the mdx, resulting from a higher rate of fibre necrosis. The 
greater amount of calcium deposits found in the diaphragms of the LV5/mdx compared to the 
mdx indicates once again a higher level of damage in the muscles of the transgenic group. 
When performing physiology on 22 week old mice, the eccentric exercise protocol reveals a 
much higher susceptibility to fibre damage in the LV5/mdx, showing that the membranes of 
the muscle fibres are much frailer in the LV5/mdx than in the mdx. 
In the case of the mdx mice, the increased glycosylation of α-DG seem to have a detrimental 
effect on the viability of the muscle fibres. More pathology is observed histologically, and a 
clear negative effect is seen on the physiology. The increased glycosylation most likely 
increases the attachment of the sarcolemma to the ECM proteins, such as perlecan, agrin and 
laminin. It seems as though the increased attachment to the ECM, in the absence of 
dystrophin to transfer the force to the internal cytoskeleton, decreases the fibre stability. 
There is also the possibility that overexpression of LARGE does not only lead to 
hyperglycosylation of α-DG, but to other components of the sarcolemma as well. This might 
also lead to an increased attachment to the ECM, but of another kind. If this is the case, the 
missing dystrophin may not be the problem, which subsequently means that treatment with 
upregulation of LARGE may prove to be unsuccessful in models for dystroglycanopathies as 
well. The study done on the LV5 transgenic mice did not reveal any histological pathology in 
any muscles, but there was an increased susceptibility to contraction-induced injury in the 
older mice (8 months old) (Brockington et al., 2010). The mdx background of our mice, 
giving them decreased muscle fibre viability to start with, may highlight and increase what 
was starting to show in the 8 month LV5 mice. 
DMD patients and the mdx mice do not have a problem in the glycosylation of α-DG to begin 
with, but yet the overexpression of another glycosyltransferase in the mdx decreases the 
pathology significantly in mdx mice (Nguyen et al., 2002; Martin et al., 2009). It has been 
shown that the loss of dystrophin in both DMD patients (Ohlendieck et al., 1993) and the mdx 
mouse (Ohlendieck & Campbell, 1991) reduces the expression of many dystrophin-associated 
proteins (DAPs) that are in the proximity or directly bound to dystrophin. These include the 
dystroglycans, dystrobrevins and sarcoglycans. In the case of the CT GalNAc transferase, the 
overexpression of this enzyme leads to restoration of normal or above normal expression of 
the DAPs (Nguyen et al., 2002) which seems to be the factor preventing the muscular 
dystrophy. LARGE only increases glycosylation, but with the decrease in α-DG and the other 
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DAPs observed in the mdx, one can wonder what other molecules on the membrane actually 
get glycosylated. Interestingly, a newly published paper by Zhang et al. (2011) showed that 
overexpressing LARGE in α-DG deficient neural stem cells still gave binding of IIH6 
antibodies, when it has been thought that they only bind to hyperglycosylated α-DG. This not 
only questions the specificity of the IIH6 immunoreativity, but also confirms that LARGE 
glycosylates at least one other molecule on the cell surface. The glycosylated molecules were 
also shown to possess the functional capacity of binding laminin. 
The presence of calcium aggregations in DMD patient biopsies has been reported for a long 
time (Bodensteiner & Engel, 1987), and the same is reported for mdx mice (Turner et al., 
1991). This is the result of a higher intracellular calcium level present in the dystrophic 
muscle fibres. There are two theories to why this is the case; one speculates that it is the result 
of tears in the debilitated membrane during eccentric contractions, the other that it is caused 
by abnormal functioning of membrane channels, mainly stretch-activated channels 
(Whitehead et al., 2006). Both of these lead to an increase in intracellular calcium, which 
means the loss of calcium homeostasis within the fibre. This subsequently triggers various 
pathways, such as proteases and reactive oxygen species, leading to fibre necrosis. In the case 
of the LV5/mdx, the greater presence of calcium deposits in the diaphragm at 8 weeks bears 
witness of an increase in the destructive process of calcium infiltration. The increased 
attachment between the sarcolemma and the ECM, leading to increased tearing of the 
membrane during eccentric exercise, would be a possible hypothesis for this finding. 
The reason for the acute onset of pathology at 3 week of age in mdx mice is not known, but 
one hypothesis is that it is caused by an increase in activity of the pups as that is generally 
when they start exploring the cage, or it could be the result of a developmental change in 
protein expression in the mouse (Grounds et al., 2008). In any case, it provides a good time 
point for comparison when evaluating potential therapies targeting a reduction of necrosis, 
which is demonstrated quite clearly here. The fact that no difference could be seen between 
the diaphragms of the two groups at 20 week may be an indication of that the pathology in the 
mdx has caught up to the one in the LV5/mdx, explaining why they both show similar levels 
of fibrosis and hypertrophy of the muscle fibres. 
LARGE has previously been overexpressed experimentally through viral vector transfer in the 
Largemyd mouse, a mouse with a spontaneous mutation in LARGE (Barresi et al., 2004). It 
serves as a mouse model for dystroglycanopathies such as muscle-eye-brain disease (MEB) 
and Fukuyama congenital muscular dystrophy (FCMD). The overexpression of LARGE 
resulted in an improved phenotype in the Largemyd mouse, decreasing the pathology. An even 
more promising result was found when the overexpression of LARGE in the knock-in mouse 
model for FCMD and in the POMGnT1 mouse model (Kanagawa et al., 2008) lead to the 
production of α-DG capable of binding laminin in both cases, although nothing is said about 
the phenotype. These are promising results for LARGE, but more research needs to be done 
using animal models for dystroglycanopathies, such as the Sox1FKRPKD (Brown et al., in 
preparation). 
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The increase in glycosylation level seen between the 3 and the 8 week old mice on the 
western blot can be attributed to an actual increase of DAPs. It has been shown that neonatal 
muscle and regenerating patches in mdx mouse muscles have a much higher expression of 
DAPs compared to mature muscle in mdx (Khurana et al., 1991). As there is a large presence 
of regenerating patches at 8 weeks, the glycosylation level becomes visible on western blot. 
Study limitations 
The counting done on total number of fibres in the 8 week individuals (appendix 1) shows 
that there was an outlier in the LV5/mdx group. We discussed excluding it, but found that this 
would only create a bias in favour of more pathology in the LV5/mdx. The larger number of 
fibres seen the in LV5/mdx group is thought to be due to fibre splitting due to defects in 
regeneration and is commonly seen in older mdx mice (Lovering et al., 2009). 
The 3 week old mice is the only time point where females are present. They were the second 
generation of the LV5/mdx cross, which meant that both sexes could be used. Unfortunately, 
the sex ratio between the two groups turned out to be very marked, which is an important 
factor that needs to be taken into account when considering the results. It has been shown that 
gender plays a role in the pathology observed in the mdx, with females showing a lower 
susceptibility to muscle damage at a young age compared to males, but a higher level of 
fibrosis when old (Salimena et al., 2004). The 3 week old mouse displaying the severest 
pathology in the mdx group turned out to be the male, and the mouse showing the least 
pathology in the LV5/mdx was the female. This indicates the need of increasing the n number 
and balancing out the sexes between the two genotypes before final conclusions to be made. 
The IIH6 staining on the 3 week mice worked, but was patchy. The presence of more 
intensely stained neuromuscular junctions in the mdx sections made it possible to identify 
when it had worked on an mdx sample. This experiment could not be repeated again because 
of time constraints but should be repeated before publication of this study. 
There is some question as to whether the statistical test done for the physiological 
measurement can be used with such low n numbers. The study was repeated with another two 
mice in each group and showed the same pattern, but with different values, which was most 
likely caused by the use of different equipment. This again needs to be repeated before the 
publication of this study. 
The WB image shows that there was some problems with the loading control as a few bands 
appear faint or missing. With regards to the LV5/mdx and the mdx samples, these were run in 
pairs and at least one of the loading controls for them worked properly. This validates the 
experiment. Additional samples run by Dr Mark Ackroyd on 8 week mice (n=3) displayed 
similar results (figure not included) which validates this further. There is also evident 
background coming through in the picture caused by non-specific binding by the antibodies, 
but again because of time constraints, the experiment could not be repeated. 
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The overexpression of the CT GalNAc transferase protected against muscular dystrophy, 
while overexpression of LARGE did not. In the CT GalNAc transferase experiment, 
protection was associated with restoration of the DAPs. The level of the DAPs in the 
LV5/mdx in comparison to the mdx needs to be investigated. 
Future work 
As well as the experiments noted above to complete the mdx/LV5 study, more research needs 
to be done in the area of LARGE overexpression, mainly with generation and analysis of 
animal models for dystroglycanopathies overexpressing LARGE. The Wells/Brown groups 
plan to examine the effects of overexpressing LARGE in Largemyd mice, Sox1FKRPKD mice 
and POMGnT1 knockout mice. Further investigations aimed at unveiling the 
glycosylationpattern of LARGE should also be done, by using western blots for example. 
This will be a more problematic task seeing as there is now further evidence of that the 
binding of IIH6 is not as specific as thought (Lin et al., 2011). 
CONCLUSION 
This study has shown that upregulation of LARGE is not a viable treatment for DMD. Instead 
of preventing the development of muscular dystrophy, it increased the severity of it and 
advanced the onset of pathology. However, this does not exclude the possibility of LARGE 
proving to be a suitable treatment for dystroglycanopathies, a group of muscular dystrophies 
with a different cause.  
In the scenario of LARGE becoming a treatment for the dystroglycanopathies, careful 
screening needs to be done of potential patients in order to exclude all patients suffering from 
DMD. The data presented in this study suggests that treating a DMD patient with LARGE 
would bring on disastrous results. 
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APPENDIX 
Appendix 1. Counts done on myofibres in mdx and LV5/mdx. Mdx mice in bold typing, LV5/mdx 
in normal typing. The LV5/mdx show a higher number in average total fibre count, and a lower 
percentage of non-centrally nucleated fibres in all animals when comparing with the mdx animals 
Sample 1st count  2nd count 3rd count Average non-centralized Tot fibers % Within group 
10/474 373 433 396 400.7 5380 7.7 
10/478 402 381   391.5   7.5 
10/482 203 240 
 
221.5 
 
3.4 
10/486 173 287 242 234   4.5 
10/490 170 174   172   2.7 
10/494 336 409 402 382.3 4725 7.3 
11/3 199 191   195 8337 3.0 
11/7 138 148   143 5402 2.2 
11/11 187 180   183.5   2.8 
11/15 476 472   474 5535 9.1 
11/19 324 315   319.5   6.1 
11/23 132 95 126 117.7 5712 1.8 
       
     
  
 
    
Average mdx 
    
5,213.3  7.0 
    
Average LV5/mdx 
     
6,483.7  2.7 
 
